Caretive® should be used with caution in patients who have a history of local reactions of hypersensitivity to other GCS. Local reactions of hypersensitivity (see section "Side effect") may resemble the symptoms of the underlying disease.
Manifestations of hypercorticism (Itenko-Cushing syndrome) and reversible inhibition of HHHC leading to glucocorticoid insufficiency, in some cases arise as a result of increased systemic absorption of GCS for external application.In such cases, it is necessary to gradually stop the treatment, reducing the frequency of application, or replace the drug Kutiveyt® with a less active SCS. A sudden cessation of treatment can lead to glucocorticoid insufficiency (see the "Side effect" section).
Risk factors for the development of severe systemic reactions include the following:
- activity and dosage form of GCS for external use:
- duration of treatment;
- application to large areas of the skin;
- application to the closed areas of the skin, for example, in diaper rash or under occlusive dressings (children may have a diaper as an occlusive dressing);
- increased hydration of the horny layer of the dermis;
- application to areas with thin skin, such as face;
- damaged skin or other conditions potentially accompanied by damage to the skin barrier;
- compared with adults in children, there is a possibility of absorption of more GCS for external use, thus increasing the risk of developing systemic adverse reactions. This is due to the immaturity of the skin barrier and a higher ratio of body surface area to body weight in children compared to adults.
Children from 1 to 12 years should avoid prolonged continuous therapy with GCS for external use whenever possible, as there is a possibility of suppression of adrenal function.
Caution should be exercised when prescribing GCS for external use in the treatment of psoriasis, as there are reports of early relapses, addiction, the risk of generalized pustular psoriasis, and local or systemic toxicity due to impaired skin barrier function. The use of psoriasis requires careful monitoring of the course of the disease in the patient.
Long-term application of Coutiveyt® cream on the face area is undesirable, since the skin in this area is more prone to atrophic changes.
When applying Coutiveyt® cream on the eyelids, care should be taken that the drug does not get into the eyes, since repeated contact of the drug with the mucous membrane of the eye can lead to the development of cataracts and glaucoma.
In the secondary infection of the skin lesions should be prescribed appropriate antibiotic therapy. In case of signs of spread of infection, it is necessary to cancel SCS for external use and to prescribe appropriate antibiotic therapy.
Bacterial infections are easier to develop in warm and humid conditions in natural folds of the skin or under occlusive dressings, therefore, the skin should be thoroughly cleaned before applying a new bandage.
SCS therapy for external use is sometimes used to treat dermatitis developing around chronic ulcers of the lower limbs. However, this may be associated with a higher incidence of local hypersensitivity reactions and infectious complications.
Explicit inhibition of the function of the GGNS (the level of cortisol in the blood plasma in the morning is less than 5 μg / dL) in adults is unlikely with the use of Kutiveyt® in recommended doses, except for the application of the preparation more than 50% of the body surface area and in excess of 20 g per day .
Kutiveyt® contains imidourea as an adjuvant, which is metabolized to form trace amounts of formaldehyde. Formaldehyde may cause an allergic reaction or irritation in contact with skin.